Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:STML
- CUSIP: N/A
- Web: www.stemline.com
Capitalization:- Market Cap: $220.9 million
- Outstanding Shares: 23,376,000
Average Prices:- 50 Day Moving Avg: $8.05
- 200 Day Moving Avg: $9.16
- 52 Week Range: $5.50 - $14.60
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.50
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.14 million
- Price / Sales: 193.77
- Book Value: $3.99 per share
- Price / Book: 2.37
Profitability:- EBIDTA: ($44,340,000.00)
- Net Margins: -3,864.20%
- Return on Equity: -60.51%
- Return on Assets: -52.80%
Debt:- Current Ratio: 6.83%
- Quick Ratio: 6.83%
Misc:- Average Volume: 177,302 shs.
- Beta: -0.16
- Short Ratio: 15.5
Frequently Asked Questions for Stemline Therapeutics (NASDAQ:STML)
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
How were Stemline Therapeutics' earnings last quarter?
Stemline Therapeutics, Inc. (NASDAQ:STML) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.22. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative return on equity of 60.51% and a negative net margin of 3,864.20%. View Stemline Therapeutics' Earnings History.
When will Stemline Therapeutics make its next earnings announcement?
Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2017?
6 equities research analysts have issued 12 month price objectives for Stemline Therapeutics' shares. Their predictions range from $16.00 to $41.00. On average, they expect Stemline Therapeutics' share price to reach $32.60 in the next year. View Analyst Ratings for Stemline Therapeutics.
What are analysts saying about Stemline Therapeutics stock?
Here are some recent quotes from research analysts about Stemline Therapeutics stock:
- 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (5/20/2017)
- 2. HC Wainwright analysts commented, "Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year." (5/15/2017)
- 3. Cowen and Company analysts commented, "STML reported 1Q17 financials and provided a pipeline update." (5/12/2017)
- 4. Jefferies Group LLC analysts commented, "We had a chance to host investor meetings with mgmt, which primarily focused on near-term SL-401 catalysts. In BPDCN, the focus was around the pot’l 2H16 meeting with FDA to determine the amount of data needed to submit a BLA. The company also presented incrementally updated data in BPDCN that was consistent with data from ASCO." (7/22/2016)
Who are some of Stemline Therapeutics' key competitors?
Some companies that are related to Stemline Therapeutics include Atara Biotherapeutics (ATRA), BioSpecifics Technologies Corp (BSTC), Rigel Pharmaceuticals (RIGL), Adaptimmune Therapeutics PLC (ADAP), BioTime (BTX), Minerva Neurosciences (NERV), Corbus Pharmaceuticals Holdings (CRBP), GlycoMimetics (GLYC), Edge Therapeutics (EDGE), Merus N.V. (MRUS), Ovid Therapeutc (OVID), Tocagen (TOCA), Immune Design Corp. (IMDZ), Ardelyx (ARDX), Chimerix (CMRX), Clearside Biomedical (CLSD), Circassia Pharmaceuticals PLC (CIR) and Catalyst Pharmaceuticals (CPRX).
Who are Stemline Therapeutics' key executives?
Stemline Therapeutics' management team includes the folowing people:
- Ivan Bergstein M.D., Chairman of the Board, President, Chief Executive Officer
- Kenneth Hoberman, Chief Operating Officer
- David G. Gionco, Chief Accounting Officer, Vice President - Finance
- Ron Bentsur, Independent Director
- J. Kevin Buchi, Independent Director
- Eric L. Dobmeier, Independent Director
- Alan S. Forman, Independent Director
- Kenneth J. Zuerblis, Independent Director
Who owns Stemline Therapeutics stock?
Stemline Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.14%), Eventide Asset Management LLC (4.33%), Vanguard Group Inc. (4.60%), AXA (2.42%), Sphera Funds Management LTD. (1.67%) and VHCP Management II LLC (1.27%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.
Who sold Stemline Therapeutics stock? Who is selling Stemline Therapeutics stock?
Stemline Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Morgan Stanley, Dimensional Fund Advisors LP and Stoneridge Investment Partners LLC. Company insiders that have sold Stemline Therapeutics stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.
Who bought Stemline Therapeutics stock? Who is buying Stemline Therapeutics stock?
Stemline Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, AXA, Sphera Funds Management LTD., Eventide Asset Management LLC, Vanguard Group Inc., Columbus Circle Investors, Cowen Group Inc. and Trexquant Investment LP. View Insider Buying and Selling for Stemline Therapeutics.
How do I buy Stemline Therapeutics stock?
Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stemline Therapeutics' stock price today?
One share of Stemline Therapeutics stock can currently be purchased for approximately $9.45.
MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Stemline Therapeutics (NASDAQ:STML)Earnings History by Quarter for Stemline Therapeutics (NASDAQ STML)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | | | | | | | |
| 5/10/2017 | Q1 2017 | ($0.45) | ($0.67) | $0.30 million | $0.30 million | View | N/A |  |
| 5/9/2016 | Q116 | ($0.59) | ($0.51) | $121.43 million | $205.65 million | View | N/A | |
| 3/14/2016 | Q4 | ($0.57) | ($0.58) | $0.15 million | $0.21 million | View | N/A | |
| 11/6/2015 | Q315 | ($0.59) | ($0.53) | $0.10 million | $0.21 million | View | N/A | |
| 8/10/2015 | Q2 | ($0.41) | ($0.58) | $0.10 million | $0.12 million | View | N/A | |
| 5/11/2015 | Q1 | ($0.45) | ($0.46) | $0.09 million | $0.12 million | View | N/A | |
| 3/13/2015 | | ($0.60) | ($0.53) | $0.07 million | $0.12 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.58) | ($0.53) | $0.07 million | $0.07 million | View | N/A | |
| 8/14/2014 | | ($0.71) | ($0.47) | $0.07 million | $0.07 million | View | N/A | |
| 5/22/2014 | | ($0.72) | ($0.70) | $0.07 million | $0.07 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)2017 EPS Consensus Estimate: ($1.98)
2018 EPS Consensus Estimate: ($1.50)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.42) | ($0.42) | ($0.42) |
| Q2 2017 | 1 | ($0.47) | ($0.47) | ($0.47) |
| Q3 2017 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q4 2017 | 1 | ($0.61) | ($0.61) | ($0.61) |
| Q1 2018 | 1 | ($0.38) | ($0.38) | ($0.38) |
| Q2 2018 | 1 | ($0.38) | ($0.38) | ($0.38) |
| Q3 2018 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q4 2018 | 1 | ($0.35) | ($0.35) | ($0.35) |
(Data provided by Zacks Investment Research)
Dividend History for Stemline Therapeutics (NASDAQ:STML)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Stemline Therapeutics (NASDAQ:STML)Insider Ownership Percentage: 15.70%
Institutional Ownership Percentage: 54.18%
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/28/2017 | David Gionco | Insider | Sell | 6,486 | $6.99 | $45,337.14 | |
| 2/28/2017 | Ivan Bergstein | CEO | Sell | 17,980 | $6.99 | $125,680.20 | |
| 2/28/2017 | Kenneth Hoberman | COO | Sell | 8,027 | $6.99 | $56,108.73 | |
| 2/27/2017 | David Gionco | CAO | Sell | 3,500 | $6.97 | $24,395.00 | |
| 2/27/2017 | Ivan Bergstein | CEO | Sell | 7,500 | $6.97 | $52,275.00 | |
| 2/27/2017 | Kenneth Hoberman | COO | Sell | 4,000 | $6.97 | $27,880.00 | |
| 2/16/2017 | Ivan Bergstein | CEO | Sell | 3,652 | $6.42 | $23,445.84 | |
| 2/16/2017 | Kenneth Hoberman | COO | Sell | 1,508 | $6.42 | $9,681.36 | |
| 1/19/2017 | David Gionco | Insider | Sell | 3,593 | $11.46 | $41,175.78 | |
| 1/10/2017 | Kenneth Hoberman | COO | Sell | 9,110 | $13.82 | $125,900.20 | |
| 3/8/2016 | David Gionco | CAO | Sell | 1,148 | $5.32 | $6,107.36 | |
| 3/8/2016 | Ivan Bergstein | CEO | Sell | 5,537 | $5.34 | $29,567.58 | |
| 3/8/2016 | Kenneth Hoberman | COO | Sell | 2,412 | $5.34 | $12,880.08 | |
| 2/17/2016 | Ivan Bergstein | CEO | Sell | 3,244 | $4.46 | $14,468.24 | |
| 2/17/2016 | Kenneth Hoberman | COO | Sell | 1,503 | $4.54 | $6,823.62 | |
| 1/20/2016 | David Gionco | CAO | Sell | 3,217 | $4.82 | $15,505.94 | |
| 11/30/2015 | Ivan Bergstein | CEO | Sell | 12,235 | $8.20 | $100,327.00 | |
| 4/27/2015 | Eric K Rowinsky | Insider | Sell | 10,824 | $15.77 | $170,694.48 | |
| 3/19/2015 | Kenneth Hoberman | COO | Sell | 17,307 | $16.43 | $284,354.01 | |
| 1/20/2015 | David Gionco | CAO | Sell | 3,311 | $14.22 | $47,082.42 | |
| 11/26/2014 | Ivan Bergstein | CEO | Sell | 11,974 | $14.40 | $172,425.60 | |
| 9/3/2014 | Ivan Bergstein | CEO | Buy | 2,000 | $11.05 | $22,100.00 | |
| 9/2/2014 | Kenneth Hoberman | COO | Buy | 2,000 | $10.99 | $21,980.00 | |
| 9/2/2014 | Kenneth J Zuerblis | Director | Buy | 1,000 | $11.14 | $11,140.00 | |
| 5/30/2013 | Kenneth J Zuerblis | Director | Buy | 3,000 | $16.01 | $48,030.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Stemline Therapeutics (NASDAQ:STML)
Latest Headlines for Stemline Therapeutics (NASDAQ:STML)
| Source: |
|
| Date | Headline |
|---|
 | Stemline Therapeutics (STML) Announces SL-401 Updated Stage 1 & 2 Data from Ongoing Pivotal Trial in BPDCN ... - StreetInsider.com
www.streetinsider.com - June 25 at 6:43 AM |
 | Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA
feeds.benzinga.com - June 23 at 10:17 AM |
 | Stemline Therapeutics Inc (STML) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 9 at 11:22 AM |
 | Stemline Therapeutics to Present at the Jefferies 2017 Healthcare ... - GlobeNewswire (press release)
globenewswire.com - June 6 at 11:18 PM |
| Stemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference
feeds.benzinga.com - June 6 at 7:46 AM |
| Stemline Therapeutics Inc (STML) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - May 31 at 3:22 PM |
 | Implied Volatility Surging for Stemline Therapeutics (STML) Stock Options
finance.yahoo.com - May 31 at 12:15 PM |
| Jefferies Group LLC Reaffirms "Buy" Rating for Stemline Therapeutics Inc (STML)
www.americanbankingnews.com - May 27 at 12:44 PM |
| Stemline Therapeutics Inc (STML) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 20 at 7:08 AM |
| Stemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHA
www.streetinsider.com - May 19 at 12:51 PM |
| Stemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 ... - StreetInsider.com
www.streetinsider.com - May 18 at 12:55 PM |
| Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting
finance.yahoo.com - May 18 at 12:55 PM |
| Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc.
finance.yahoo.com - May 16 at 7:59 PM |
| Stemline Therapeutics Inc (STML) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 15 at 4:28 PM |
| Stemline Therapeutics Inc (STML) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 11:22 AM |
| Brokers Offer Predictions for Stemline Therapeutics Inc's Q2 2017 Earnings (STML)
www.americanbankingnews.com - May 15 at 7:26 AM |
| Analysts Offer Predictions for Stemline Therapeutics Inc's Q1 2018 Earnings (STML)
www.americanbankingnews.com - May 12 at 4:08 PM |
| Stemline Therapeutics Inc (STML) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - May 12 at 1:38 PM |
| Wedbush Reaffirms Outperform Rating for Stemline Therapeutics Inc (STML)
www.americanbankingnews.com - May 11 at 5:24 PM |
| Stemline Therapeutics Inc (STML) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 4:29 PM |
| Stemline Therapeutics Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 1:19 AM |
| Stemline Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 1:19 AM |
| Stemline Therapeutics reports 1Q loss
finance.yahoo.com - May 11 at 1:19 AM |
| Favorable News Coverage Extremely Likely to Affect Stemline Therapeutics (STML) Stock Price
www.americanbankingnews.com - May 3 at 11:22 AM |
| J&W Investigates Investment Technology Group (ITG) and Stemline Therapeutics (STML); Should Officers and Directors be Responsible for Alleged Harm to the Company?
finance.yahoo.com - May 3 at 10:35 AM |
| Stemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - May 1 at 11:23 AM |
| Stemline Therapeutics (STML) Getting Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 5:45 PM |
| Stemline Therapeutics (STML) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 8:46 PM |
 | Research Reports Coverage on Biotech Stocks -- Novan, Stemline Therapeutics, BioDelivery Sciences, and ... - PR Newswire (press release)
www.prnewswire.com - April 25 at 9:35 AM |
| Stemline Therapeutics (STML) Receives Daily News Sentiment Score of 0.16
www.americanbankingnews.com - April 24 at 7:22 PM |
| Somewhat Favorable News Coverage Likely to Affect Stemline Therapeutics (STML) Stock Price
www.americanbankingnews.com - April 21 at 11:00 PM |
| Stemline Therapeutics Inc (STML) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 21 at 7:24 PM |
| Stemline Therapeutics (STML) Given Daily News Impact Score of 0.23
www.americanbankingnews.com - April 18 at 3:38 PM |
| Stemline Therapeutics Inc (STML) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 12:28 PM |
| Stemline Therapeutics (STML) Given Media Impact Score of 0.23
www.americanbankingnews.com - April 15 at 3:17 PM |
| DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. - Lead Plaintiff Deadline of April 4, 2017 - STML
finance.yahoo.com - April 3 at 7:47 PM |
| FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
finance.yahoo.com - April 3 at 7:47 PM |
| DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 3 at 7:47 PM |
| STEMLINE 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND …
finance.yahoo.com - April 1 at 10:14 AM |
| UPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM |
| DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline ... - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM |
| April 4 Deadline Alert: Law Offices of Howard G. Smith Reminds Stemline Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
finance.yahoo.com - March 31 at 3:20 PM |
| DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 3:20 PM |
| STML UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017
finance.yahoo.com - March 31 at 3:20 PM |
| UPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 3:20 PM |
| APRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, …
finance.yahoo.com - March 31 at 1:30 AM |
 | Deadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc.
us.rd.yahoo.com - March 31 at 1:30 AM |
| APRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - March 30 at 10:06 PM |
| DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline: April 4, 2017
finance.yahoo.com - March 30 at 8:29 PM |
| DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 8:29 PM |
Stemline Therapeutics (STML) Chart for Tuesday, June, 27, 2017
